{"id":"W3032176512","doi":"10.1200/jco.2020.38.15_suppl.1055","title":"Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Neutropenia; Tolerability; Internal medicine; Population; Adverse effect; Phases of clinical research; Nausea; Febrile neutropenia; Gastroenterology; Surgery; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005132022,0.0007529114,0.001307601,0.0006960691,0.0002418403,0.001155276,0.0006595892,0.0007550936,0.005552887],"category_scores_gemma":[0.006201151,0.0003435441,0.001549212,0.0008794985,0.0001678625,0.0006791487,0.0004952239,0.001543103,0.0008529482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008817166,"about_ca_system_score_gemma":0.001344915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002230116,"about_ca_topic_score_gemma":0.007090205,"domain_scores_codex":[0.9988784,0.0005071121,0.0001258315,0.00009211123,0.0002971601,0.00009924593],"domain_scores_gemma":[0.996618,0.001161295,0.001175778,0.0002043784,0.0004910482,0.0003495596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4630042,0.003015847,0.03167707,0.01067436,0.01641643,0.0005739974,0.0002416605,0.003401578,0.01579848,0.0008791399,0.1328488,0.3214685],"study_design_scores_gemma":[0.4298885,0.0636823,0.2634325,0.002136694,0.04287441,0.002154483,0.0001843333,0.001986054,0.005826316,0.001644092,0.1860019,0.0001885335],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5805164,0.1656529,0.004714679,0.007809444,0.002810346,0.007421406,0.1942206,0.0005965923,0.03625767],"genre_scores_gemma":[0.76967,0.02985555,0.007342176,0.009267886,0.001266709,0.004032599,0.1679142,0.0001717663,0.01047913],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005552887,"threshold_uncertainty_score":0.02714103,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1977987316976941,"score_gpt":0.5158389428914423,"score_spread":0.3180402111937481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}